Aytu BioScience Inc Aktie News

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Q...

Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business $19.8 million cash balance at March 31, 2024 Compa...

DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and ...

Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 million Q2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023 $19.5 million cash balance at December 31, 2023 Company to host conference call and webcast today, February 14,...

DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024. The Company has scheduled a confer...

DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024. C...